Early Response to Calcipotriol and Betamethasone Dipropionate PAD-Cream at Week 4 in Patients with Mild-to-Moderate Plaque Psoriasis: A Post-Hoc Pooled Analysis of Two Phase III Trials - Top-Institutions - MDSpire

Early Response to Calcipotriol and Betamethasone Dipropionate PAD-Cream at Week 4 in Patients with Mild-to-Moderate Plaque Psoriasis: A Post-Hoc Pooled Analysis of Two Phase III Trials

  • By

  • Maria Esposito

  • Juan Manuel Morón-Ocaña

  • Aditya K. Gupta

  • Jordi Galván

  • Ayoub Bentohami

  • Frank Freischläger

  • July 1, 2026

  • 0 min

Share

Top Institutions in Dermatology

Brief introduction explaining scope and methodology.

  • #1

    Ethikkommission der Ärztekammer
    Ethikkommission der Ärztekammer

    Hamburg, Germany

    Key Differentiators

    • Ethics Committee

  • #2

    Quorum
    Quorum

    Seattle, WA

    Key Differentiators

    • Institutional Review Board

  • #3

    Radboud University Medical Centre
    Radboud University Medical Centre

    Nijmegen, Netherlands

    Key Differentiators

    • Dermatology

  • #4

    PHARMO Database Network
    PHARMO Database Network

    Utrecht, Netherlands

    Key Differentiators

    • Health Data

  • #5

    Danish National Prescription Registry
    Danish National Prescription Registry

    Copenhagen, Denmark

    Key Differentiators

    • Health Data

Original Source(s)

Early Response to Calcipotriol and Betamethasone Dipropionate PAD-Cream at Week 4 in Patients with Mild-to-Moderate Plaque Psoriasis: A Post-Hoc Pooled Analysis of Two Phase III Trials

  • by Maria Esposito, Juan Manuel Morón-Ocaña, Aditya K. Gupta, Jordi Galván, Ayoub Bentohami, Frank Freischläger

  • July 1, 2026

Related Content

Case Report: Paradoxical psoriasis under TNF-α blockade may represent generalized abscessing staphyloderma – GASD syndrome by TNF antagonists

FDA Approves Pediatric Risankizumab

Approval expands risankizumab use to pediatric plaque psoriasis and psoriatic arthritis and includes a new 55-mg prefilled syringe for weight-based dosing in patients weighing less than 40 kg.

Zasocitinib (TAK-279), a Highly Selective Oral TYK2 Inhibitor, Demonstrates Skin Clearance in Patients with Moderate-to-Severe Plaque Psoriasis: Post Hoc Analyses of a Randomized Phase IIb Trial